提醒:代购产品,无质量问题不接受退换货,下单前请仔细核对信息。下单后请及时联系客服 核对商品价格,订单生效后再付款。
Qiagen/therascreen FGFR RGQ RT-PCR Kit (US)/For 50 RNA preps: RNeasy MinElute Spin Columns, Collection Tubes, Elution Tubes, Deparaffinization Solution, Proteinase K, RNase-Free DNase I, DNase Booster Buffer, RNase-Free Buffers and RNase-Free Wat
价格:

自营商城

解放采购

正品保障

及时交付

厂家直采

一站服务

货号:
品牌:
会员服务:
尊享会员价
贵宾专线
运费优惠
闪电退款
福利优惠
上门换新
友情提示
以上价格仅为参考,请联系客服询价。
免费咨询热线
4000-520-616
产品说明
Diagnostics & Clinical ResearchInfectious Disease5Oncology4Sample Processing121Sexual & Reproductive Health0Solutions for Laboratory-Developed Tests15TB Management2therascreen FGFR RGQ RT-PCR Kit (US)Print For qualitative detection of actionable alterations in the FGFR3 geneThe only FDA-approved FGFR alteration assay on the marketDetection of four point mutations and two fusions in the FGFR3 geneHigh sensitivity and specificitySimple workflow with next-day resultsAutomated data analysis using Rotor-Gene AssayManager v2.1 softwareThe therascreen FGFR RGQ RT-PCR Kit is a qualitative in vitro diagnostic test for the detection of two point mutations in exon 7 [p.R248C (c.742C>T), p.S249C (c.746C>G)], two point mutations in exon 10 [p.G370C (c.1108G>T) and p.Y373C (c.1118A>G)] and two fusions (FGFR3:TACC3v1 and FGFR3:TACC3v3) in the FGFR3 gene.The therascreen FGFR RGQ RT-PCR Kit is the only FDA-approved companion diagnostic (CDx) test for the identification of patients with cases of urothelial cancer (UC) that harbor these actionable FGFR alterations, and for whom treatment with BALVERSA (erdafitinib) is indicated.Buy ProductsProduct DetailsProduct ResourcesBuy ProductsCat No./ID:73604RNeasy DSP FFPE Kit$491.00Order ProductFor 50 RNA preps: RNeasy MinElute Spin Columns, Collection Tubes, Elution Tubes, Deparaffinization Solution, Proteinase K, RNase-Free DNase I, DNase Booster Buffer, RNase-Free Buffers and RNase-Free WaterCat No./ID:874721therascreen FGFR RGQ RT-PCR Kit (24)InquireFor 24 reactions: Reverse Transcriptase, RT Buffer 1, RT Buffer 2, RT Primer Mix, Mutations-1 Reaction Mix, Mutations-2 Reaction Mix, Fusions-1 Reaction Mix, Fusions-2 Reaction Mix, Water for NTC, Water for sample dil., FGFR Positive Control, PC DiluentCat No./ID:9002035Rotor-Gene Q MDx Platform (US)InquireReal-time PCR cycler with 6 channels (the red and HRM channels are not intended for use with FDA cleared or approved nucleic acid tests), laptop computer, software, accessories, 1-year warranty on parts and laborCat No./ID:9002036Rotor-Gene Q MDx System (US)InquireReal-time PCR cycler with 6 channels (the red and HRM channels are not intended for use with FDA cleared or approved nucleic acid tests), laptop computer, software, accessories, 1-year warranty on parts and labor, installation and trainingCat No./ID:9024203-USRotor-Gene AssayManager v2.1InquireSoftware for routine testing in combination withRotor-Gene Q MDxinstruments. IMPORTANT: Does not include license for use. License keymust be purchased separately. Visit the Download Page for download, installation and licensinginstructions.Cat No./ID:9025620Rotor-Gene AssayManager v2.1 License (1)InquireSingle license for the installation of Rotor-Gene AssayManager v2.1 software on one computer. For installation on multiple computers, each computer requiresan individual computer-specificlicense key.Visit the Download Page for software download, installation and licensinginstructions.Product Details In vitro diagnostic medical device.PerformanceConcordance between the clinical trial assay (CTA) used to identify patients for recruitment to the Phase 2 clinical trial of BALVERSA (42756493-BLC2001) and the therascreen FGFR RGQ RT-PCR Kit (CDx) was evaluated in a bridging study (1).Samples with valid results for both therascreen FGFR RGQ RT-PCR Kit and CTA (279/287 patients; 97.2%) were analyzed to assess the positive percent agreement (PPA), negative percent agreement (NPA) and overall percent agreement (OPA), based on agreement between the two methods for overall FGFR gene alteration status (i.e., FGFR Alteration Detected or FGFR Alteration Not Detected) Results are shown in Table 1.Table 1. therascreen FGFR RGQ RT-PCR Kit versus CTA (with CTA as reference method)Measure of agreementPercent agreement, % (N)Two-sided 95% CIPositive percent agreement85.2% (69/81)75.9, 91.3Negative percent agreement*97.0% (192/198)93.5, 98.6Overall percent agreement93.5% (261/279)90.0, 96.1* Prior chemotherapy information was not collected for CTA-negative patients. Therefore, 198 CTA-negative subjects included both chemo-relapsed/chemo-refractory patients and chemo-naïve patients.The primary objective of the BLC2001 clinical trial was to evaluate the objective response rate (ORR) to treatment with BALVERSA in subjects with cases of UC in which FGFR alterations were detected. ORR was defined as complete response (CR) plus partial response (PR) by RECIST criteria, as assessed by blinded independent review committee (BIRC). The observed clinical benefit of treatment with BALVERSA in the subset of patients in which FGFR alterations were detected with both the therascreen FGFR RGQ RT-PCR Kit and the CTA (n = 69) was comparable to that observed in the full study population, as defined by the CTA only (n = 87). The ORR in patients in whom FGFR alterations were detected by both the therascreen FGFR RGQ RT-PCR Kit and the CTA, as assessed by BIRC, was 33.3% (95% CI: 23.4-45.1%).The therascreen FGFR RGQ RT-PCR Kit is therefore indicated for use as an aid in identifying patients with cases of urothelial cancer which harbor these alterations and are therefore eligible for treatment with BALVERSA (erdafinitib).PrincipleThe therascreen FGFR RGQ RT-PCR assay is based on the selective amplification of alterations in the FGFR genes using the Rotor-Gene Q MDx (US) instrument for sensitive and specific analysis. The assay exploits the qPCR oligonucleotide hydrolysis principle using TaqMan probes.Allele-specific technology allows accurate and highly reproducible detection of alterations, based on the use of specific forward and reverse primers and probes; only a perfect match between the primers and probes with the target cDNA allows extension and amplification in the PCR reaction. Result reporting is fully automated. If both the run controls and the sample results are valid and sufficient assay target amplification occurs below the predetermined cycle number cutoff threshold, the report will show the FGFR alteration(s) detected in each sample.ProcedureThe fast and simple workflow takes ~12 hours from Sample to Insight.RNA is first prepared from formalin-fixed paraffin-embedded (FFPE) urothelial tumor samples using the RNeasy DSP FFPE Kit. Purified RNA is then reverse transcribed using Reverse Transcriptase to generate cDNA for real-time PCR analysis. Optimized ready-to-use reverse transcription reagents and PCR master mixes provided in the kit enable high-fidelity reverse transcription and sensitive real-time PCR on the Rotor-Gene Q MDx (US) instrument. Qualitative results are displayed in Rotor-Gene AssayManager software, informing the system operator if one or more of the four point mutations and two fusions in the FGFR3 gene detected by the kit are present.The therascreen FGFR RGQ RT-PCR kit is also designed to identify FGFR2 fusions FGFR2:BICC1 and FGFR2:CASP7 and FGFR3 fusion FGFR3:BAIAP2L1, because patients harboring these FGFR fusions were eligible for the BLC2001 clinical trial. However, the test is not clinically validated to detect these three fusions. Drug safety and efficacy has not been established for cases of UC harboring these fusions and no claims are made for the use of the therascreen FGFR RGQ RT-PCR kit as an aid in the selection of such patients for treatment with BALVERSA (erdafitinib).ApplicationsThe therascreen FGFR RGQ RT-PCR Kit enables qualitative detection of four point mutations and two fusions of the FGFR3 gene for in vitro diagnostic use. It is the only FDA-approved CDx assay for the selection of patients with cases of urothelial cancer (UC) harboring actionable alterations, for whom treatment with BALVERSA (erdafitinib) is indicated.1. Janssen Biotech, Inc. Data on file.Product Resourcesfragment fix placeholderCustomers who bought these products also boughtCat No./ID:9001600Rotor-Disc 72 Starter Kit (115V)4 Rotor-Disc 72 packs for 20–25 µl reactions, Rotor-Disc Heat Sealer, Rotor-Disc Heat Sealing Film, Rotor-Disc 72 Rotor and Locking Ring, Rotor-Disc 72 Loading Block, Rotor-Disc Pipetting Aid$3,932.00Add To CartCat No./ID:9022737Rotor-Gene AssayManagerSoftware for routine testing in combination with the Rotor-Gene Q and QIAsymphony RGQ instruments; single license software for installation on one computer$5,046.00Add To CartCat No./ID:9001602Rotor-Disc 100 Starter Kit (115V)3 Rotor-Disc 100 packs for 15–25 µl reaction volumes, Rotor-Disc Heat Sealer, Rotor-Disc Heat Sealing Film, Rotor-Disc 100 Rotor and Locking Ring, Rotor-Disc Pipetting Aid, Rotor-Disc Easy Lift Adaptor$4,047.00Add To CartCat No./ID:60404QIAamp DSP DNA FFPE Tissue Kit (50)For 50 DNA preps: QIAamp MinElute columns, ProteinaseK, Buffers, and Collection Tubes (2ml)$269.00Add To CartCat No./ID:61504QIAamp DSP Circulating NA KitFor 50 preps: includes QIAamp Mini Columns, Buffers, Carrier RNA, QIAGEN Proteinase K, and Tubes.$1,309.00Add To CartCat No./ID:74524RNeasy Protect Bacteria Mini Kit (50)RNeasy Mini Kit (50) and RNAprotect Bacteria Reagent (2 x 100 ml)$528.00Add To CartCat No./ID:929560QX DNA Size Marker 25–500bp (50 ul) v2.0DNA size marker with fragments of 25, 50, 75, 100, 150, 200, 250, 300, 400, and 500 bp; concentration 100 ng/ul$83.70Add To CartCat No./ID:19585S-Blocks (24)96-well blocks with 2.2 ml wells, 24 per case$348.00Add To CartCat No./ID:764133PAXgene Bone Marrow RNA Kit (30)For 30 RNA preps: 30 PAXgene Spin Columns, 30PAXgene Shredder Spin Columns, Processing Tubes, RNase-free DNase I, RNase-free reagents and buffers. To be used in conjunction with PAXgene Bone Marrow RNA Tubes$707.00Add To CartCat No./ID:51804QIAamp PowerFecal ProDNA KitFor the isolation of microbial DNA from stool and gut samples$356.00Add To CartCat No./ID:981106Strip Tubes and Caps, 0.1 ml (2500)10 x 250 strips of 4 tubes and caps for 10,000 reactions of 10–50 µl$2,039.00Add To CartCat No./ID:929530 QX Alignment Marker 15 bp/600 bp (1.5 ml) Alignment marker with 15 bp and 600 bp fragments$97.00Add To CartCat No./ID:52904QIAamp Viral RNA Mini Kit (50)For 50 RNA preps: 50 QIAamp Mini Spin Columns, carrier RNA, Collection Tubes (2 ml), RNase-free buffers$271.00Add To CartCat No./ID:52304QIAamp RNA Blood Mini Kit (50)For 50 RNA preps: 50 QIAamp Mini Spin Columns, 50 QIAshredder Spin Columns, Collection Tubes (1.5 ml and 2 ml), RNase-free reagents and buffers$385.00Add To CartCat No./ID:622120QuantiFERON-TB Gold Plus 2 Plate Kit ELISAMicroplate Strips; IFN-gamma Standard, lyophilized; Green Diluent; Conjugate 100x Concentrate, lyophilized; Wash Buffer 20x Concentrate; Enzyme Substrate Solution; Enzyme Stopping SolutionAdd To CartCat No./ID:981103Strip Tubes and Caps, 0.1 ml (250)250 strips of 4 tubes and caps for 1000 reactions of 10–50 µl$250.00Add To CartCat No./ID:28706QIAquick Gel Extraction Kit (250)For gel extraction or cleanup of 250 reactions: 250 QIAquick Spin Columns, Buffers, Collection Tubes (2 ml)$579.00Add To CartCat No./ID:158467Gentra Puregene Blood Kit (120 ml)For 120 ml blood: RBC Lysis Solution, RNase A Solution, and Reagents$306.00Add To CartCat No./ID:201443 Taq PCR Master Mix Kit (250 U)3 x 1.7 ml Taq PCR Master Mix containing 250 units Taq DNA Polymerase, 3 x 1.7 ml Distilled water$99.70Add To CartCat No./ID:622526QFT-Plus Blood Collection Tubes (200)QFT-Plus Blood Collection Tubes: Nil, TB1, TB2, and Mitogen tubes (50 each)Add To Cart

QIAGEN是一家专业化致力于生物分子样品制备解决方案的跨国经营企业,总部位于德国。1984年,QIAGEN在德国成立,1996年在美国纽约纳斯达克上市。

QIAGEN拥有超过1000项专利和认可证明,在18个国家设立了分公司,代理商服务国超过40个,在全球有超过400000的用户。QIAGEN提供的产品超过500类,包括各种试剂,耗材和自动化纯化工作站。这些产品用于样品采集,稳定,核酸或蛋白的分离,纯化和检测中,不仅广泛的应用于科研领域的各个方面,在生物技术,制药,法医研究,食品安全检测,畜牧业和分子诊断领域也得到了广泛的应用。QIAGEN产品的卓越品质和在应用中的出色表现使得其成为样品处理中标准的代名词。


客服在线
service-logo
已有 人查看该问题
tel
全国免费服务热线
4000-520-616
微信公众号
关注我们
手机扫码,关注动态